(0.34%) 5 117.37 points
(0.34%) 38 368 points
(0.39%) 15 990 points
(-0.97%) $83.04
(5.36%) $2.03
(0.34%) $2 355.20
(0.50%) $27.67
(4.11%) $960.00
(-0.26%) $0.932
(-0.44%) $10.98
(-0.57%) $0.796
(1.66%) $93.40
Live Chart Being Loaded With Signals
Immuron Limited, a biopharmaceutical company, researches, develops, and commercializes polyclonal antibodies in Australia, the United States, and internationally...
Stats | |
---|---|
本日の出来高 | 4 616.00 |
平均出来高 | 919 446 |
時価総額 | 14.53M |
EPS | $0 ( 2023-08-30 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -5.80 |
ATR14 | $0 (0.00%) |
Immuron Limited 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Immuron Limited 財務諸表
Annual | 2023 |
収益: | $1.80M |
総利益: | $1.31M (72.54 %) |
EPS: | $-0.0166 |
FY | 2023 |
収益: | $1.80M |
総利益: | $1.31M (72.54 %) |
EPS: | $-0.0166 |
FY | 2022 |
収益: | $765 193 |
総利益: | $523 502 (68.41 %) |
EPS: | $-0.0114 |
FY | 2021 |
収益: | $145 776 |
総利益: | $94 705.00 (64.97 %) |
EPS: | $-1.516 |
Financial Reports:
No articles found.
Immuron Limited
Immuron Limited, a biopharmaceutical company, researches, develops, and commercializes polyclonal antibodies in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It markets Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and reduce the symptoms of minor gastro-intestinal disorders, as well as for dietary supplement for digestive tract protection; and Protectyn, an immune supplement to maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) that is in Phase III clinical trials to reduce the risk of contracting travelers' diarrhea, as well as acts as an anti-viral activity against SARS-CoV-2; and IMM-529, which is in clinical development stage focuses on treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and ETEC infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is based in Carlton, Australia.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。